This is a prospective single-center, phase IIa, single arm, open label, interventional proof-of-concept study conducted in 8 patients with idiopathic pulmonary arterial hypertension receiving stable therapy. Patients will receive standard treatment plus 10 mg once daily empagliflozin oral tablets for 12 weeks. The primary endpoints of the study are safety, feasibility and tolerability of treatment with empagliflozin. This study should explore whether conducting a randomized double blind placebo controlled study with empagliflozin treatment is feasible, safe for the patient and well tolerated by study participants. The explore potential benefit of treatment with empagliflozin, subjects will receive an MRI and ultrasound of the heart, blood biomarkers will be assessed, a six minute walking test will be conducted and two questionnaires will be administered. During treatment, the hospital will be visited to closely monitor funcational class and the safety of the drug through blood and physical examination. Adverse events will be accurately registered.
The aim of the study is to determine whether conducting a randomized placebo-controlled clinical trial is feasible, safe for the patient and whether the treatment is well tolerated in patients with idiopathic pulmonary arterial hypertension.